证券代码：300573 证券简称：兴齐眼药 公告编号：2026-010 药品通用名称：溴莫尼定噻吗洛尔滴眼液 沈阳兴齐眼药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 英文名/拉丁名：Brimonidine Tartrate and Timolol Maleate Eye Drops 剂型：眼用制剂 规格：5ml：酒石酸溴莫尼定 10.0mg 和马来酸噻吗洛尔 25.0mg（按 C13H24N4O3S 计） 注册分类：化学药品 4 类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 上市许可持有人名称：沈阳兴齐眼药股份有限公司 今日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的溴莫尼定噻吗洛尔滴眼液《药品 注册证书》。现将有关事宜公告如下： 一、药品基本情况 本品是以酒石酸溴莫尼定和马来酸噻吗洛尔为活性成份的复方滴眼液，公司 本次获批的溴莫尼定噻吗洛尔滴眼液为多剂量规格产品，适应症为用 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2026-009 沈阳兴齐眼药股份有限公司 关于SQ-24071滴眼液I期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 适应症：拟用于延缓儿童及青少年的近视进展 临床试验批准通知书编号：2026LP00170、2026LP00171、2026LP00172、 2026LP00173 临床试验分期：I期 二、临床试验相关情况 近视通常是眼球前后轴过长所致，也可能由角膜过度弯曲和（或）晶状体屈 光能力过强造成。当人眼处于调节放松状态时，平行光线经眼球的折光系统（角 膜、房水、晶状体和玻璃体等）聚焦于视网膜之前，使视网膜上无法清晰成像， 从而表现为近视。SQ-24071滴眼液是公司开发的一款用于延缓近视进展的药物， 本次开展的I期研究为一项单中心、随机、双盲、安慰剂对照的临床试验，目的 是评估SQ-24071滴眼液在健康参与者中单次/多次给药的安全性和耐受性，并分 析评价全身暴露量，评估药物的药代动力学（PK）特征。 三、同类药品的情况 沈阳兴齐眼药股份有限公司（以下简称"公司"） ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2026-008 沈阳兴齐眼药股份有限公司 关于投资设立全资子公司并取得营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据沈阳兴齐眼药股份有限公司（以下简称"公司"）战略发展规划，为进 一步增强综合竞争优势，公司以自有资金 5,000 万元设立全资子公司北京兴齐生 物技术有限公司（以下简称"北京兴齐"）。 根据《深圳证券交易所创业板股票上市规则》《公司章程》等有关规定，本 次设立全资子公司事项无需提交董事会、股东会审议，不涉及关联交易，亦不构 成《上市公司重大资产重组管理办法》规定的重大资产重组。 一、设立全资子公司的基本情况 今日，北京兴齐完成了工商注册登记手续并取得了北京经济技术开发区市场 监督管理局颁发的营业执照，基本情况如下： 2、名称：北京兴齐生物技术有限公司 3、类型：有限责任公司（法人独资） 4、法定代表人：杨强 5、经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技 术转让、技术推广。（除依法须经批准的项目外，凭营业执照依法自主开展经营 活动）许可项目：药品生产 ...

沈阳兴齐眼药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 今日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的平衡盐溶液（供灌注用）《药品注 册证书》。现将有关事宜公告如下： 一、药品基本情况 药品通用名称：平衡盐溶液（供灌注用） 证券代码：300573 证券简称：兴齐眼药 公告编号：2026-007 注册地址：辽宁省沈阳市浑南区新运河路 25 号 生产企业名称：哈尔滨三联药业股份有限公司 生产地址：哈尔滨市利民开发区北京路 药品批准文号：国药准字 H20263503 英文名/拉丁名：Balanced Salt Solution Irrigating 剂型：冲洗剂 规格：500mL（氯化钙 0.48mg/mL；氯化镁 0.3mg/mL；氯化钾 0.75mg/mL； 醋酸钠 3.9mg/mL；氯化钠 6.4mg/mL；枸橼酸钠 1.7mg/mL） 注册分类：化学药品 4 类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要 ...

Core Insights - The China Securities Medicine and Medical Device Innovation Index (931484) shows mixed performance among its constituent stocks, with New and Achieve leading the gains at 3.63% [1] - The Medical Innovation ETF (516820) has seen a net inflow of 12.6971 million yuan over the past three days, with a peak single-day inflow of 6.1732 million yuan [1] - The current phase of brain-computer interface technology is described as an explosive period, with multiple countries, including China, accelerating their strategic positioning in global brain science [1] - AI is transitioning from a supportive role to becoming a core driver of value reconstruction and efficiency revolution in the medical industry, impacting various sectors such as medical imaging and drug development [1] Industry Overview - The Medical Innovation ETF closely tracks the China Securities Medicine and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]

Group 1 - The company acknowledges the concern regarding the rapid decline in newborns in China and states it will continue to monitor industry and macroeconomic changes [1] - The company focuses on the ophthalmic pharmaceutical sector, with products catering to all age groups, indicating a broad market approach [1] - The company emphasizes its commitment to enhancing core competitiveness and operational quality while maintaining focus on its main business [1]

Core Viewpoint - The company, Xingqi Eye Pharmaceutical, is committed to focusing on the ophthalmic pharmaceutical sector and enhancing its core competitiveness and operational quality while monitoring changes in the industry and macroeconomic environment [2]. Group 1: Company Focus - The company specializes in ophthalmic pharmaceuticals, offering products that cater to all age groups [2]. - The company plans to continue concentrating on its main business and improving its core competitiveness [2]. Group 2: Industry and Macro Environment - The company will keep a close watch on changes in the industry and external macroeconomic conditions [2]. - Future operational details will be provided through official announcements [2].

Investment Rating - The report does not explicitly state an investment rating for the dry eye disease treatment industry Core Insights - The dry eye disease market in China is experiencing significant growth, with the number of patients increasing from 300 million in 2020 to 360 million in 2024, representing a compound annual growth rate (CAGR) of approximately 5% [7] - The treatment rate for dry eye disease remains low at 10%-12%, indicating substantial market potential [3] - The market is evolving from traditional artificial tears to innovative therapies, including preservative-free formulations and new drug delivery systems, driven by advancements in formulation technology [3] - Local pharmaceutical companies are making breakthroughs in anti-inflammatory mechanisms and targeted therapies, leading to a new competitive landscape focused on innovative drugs and precision treatment [3] Market Background - The dry eye disease market has evolved through three stages: the nascent stage (1995-2005), the initiation stage (2006-2015), and the rapid development stage (2016-present) [5][6] - The current market is characterized by a shift from foreign dominance to a competitive landscape involving both domestic and foreign companies [12] Market Status - The market size is projected to reach 139 billion yuan in 2024, with expectations to grow to 193 billion yuan by 2030, reflecting a CAGR of about 9% [7] - The supply chain includes high-activity raw materials and a diverse range of products, with foreign companies currently holding a significant market share in artificial tears [8] - Demand for treatments is increasing, particularly among moderate to severe dry eye patients who require combination therapies [9] Market Competition - The competitive landscape is marked by a clear tiered structure, with leading companies like Santen Pharmaceutical and domestic firms like Xingqi Eye Medicine dominating the first tier [12] - The report identifies ten key brands in the market, highlighting their strengths and market positions [13] - Domestic companies are increasingly closing the gap with foreign firms through innovation and strategic partnerships [12] Development Trends - The market is expected to maintain a growth rate of around 9% from 2025 to 2030, driven by advancements in diagnostic technologies and innovative therapies [27] - Drug innovation is diversifying, with traditional drugs being upgraded and new treatment modalities emerging [28] - Local companies are expanding globally, with firms like Heng Rui Medicine and Xingqi Eye Medicine leading the charge in international markets [29]

Core Viewpoint - The company emphasizes the importance of market capitalization management and actively communicates its investment value to the market through various strategies [2] Group 1: Company Strategy - The company focuses on its core business and operates steadily to enhance its market presence [2] - It fulfills its information disclosure obligations to maintain transparency with investors [2] - The management's performance assessment is linked to their responsibilities, risks, and the company's operational performance [2]

Group 1 - The core viewpoint of the article is that the company is optimistic about the potential growth of its investment in Tai Zhou Xing Pu Tai Biopharmaceutical Co., Ltd. due to the upcoming large-scale market entry of domestic oral semaglutide this year [2] - The company currently holds a 3.33% stake in Tai Zhou Xing Pu Tai Biopharmaceutical Co., Ltd., indicating a strategic investment aimed at enhancing its position within the industry supply chain [2]